Public health activists estimate Roche earned significantly more from risdiplam, a spinal muscular atrophy drug, than its ...

A recent report in The Times of India reveals that Roche may have profited immensely from risdiplam, a drug for spinal ...

Its current lead drug candidate -- apitegromab, a medicine that preserves muscle mass in patients with two types of spinal muscular atrophy (SMA) -- is under review for approval by both the U.S ...

Scholar Rock Holding Corporation's apitegromab shows promise for SMA treatment, aims for 2025 launch. Click for my updated ...

Zolgensma is a prescription drug that’s used to treat spinal muscular atrophy (SMA) in young children. Zolgensma’s cost may depend on factors such as your child’s treatment plan and whether ...

Comedian Samay Raina faces legal trouble again. The Supreme Court is upset about his alleged insensitive comments. These ...

If the government was to provide Rs 50 lakh to 1,800 patients of SMA, it would cost Rs 90,000 crore and yet not afford them even a year’s worth of medicines at the drug’s current price.

Comedian Samay Raina faces increased legal scrutiny as the Supreme Court adds him to the Ranveer Allahbadia case, disturbed ...

Biotech stock Scholar Rock (NASDAQ: SRRK) was popular among investors on Wednesday after a positive new analyst note on the ...